Drugs for Colorectal Cancer

Table. Drugs Prescribed for Colorectal Cancer

• Drug name (generic name)
• Drug company
• Indications
• Patient support services

Drug name (generic name)
• Avastin (bevacizumab) Injection
Drug company
• Genentech
Indication
• First-line or second-line therapy for metastatic colorectal cancer, in combination with IV-based chemotherapy
  
  Second-line treatment, in combination with a chemotherapy regimen, for metastatic colorectal cancer that progressed with a first-line Avastin-containing regimen
Patient support services
• Genentech Oncology Co‑pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Braftovi (encorafenib) Capsules
Drug company
• Pfizer
Indications
• Treatment of adults with metastatic colorectal cancer and BRAF V600E mutation, as detected by an FDA-approved test
Patient support services
• Co‑pay Assistance Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Camptosar (irinotecan hydrochloride) Injection
Drug company
• Pfizer
Indications
• First-line therapy for metastatic carcinoma of the colon or rectum, in combination with 5-fluorouracil and leucovorin
  
  Second-line therapy for metastatic carcinoma of the colon or rectum, after chemotherapy
Patient support services
• Pfizer Patient Assistance Program
  877-744-5675

Drug name (generic name)
• Cyramza (ramucirumab) Injection
Drug company
• Eli Lilly
Indications
• Treatment of metastatic colorectal cancer that is progressing during or after therapy with Avastin, Eloxatin, and a chemotherapy regimen
Patient support services
• Lilly Oncology Infused Products Co‑pay Program
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Erbitux (cetuximab)
Drug company
• Eli Lilly
Indication
• First-line treatment of patients with EGFR-expressing, but without KRAS mutation, metastatic colorectal cancer, in combination with a chemotherapy regimen, after previous therapy
  
  Treatment, in combination with irinotecan chemotherapy, of colorectal cancer that progressed after irinotecan, or alone in patients who cannot tolerate irinotecan
  
  Treatment, in combination with Braftovi, of adults with metastatic colorectal cancer and BRAF V600E mutation, as detected by an FDAapproved test
Patient support services
• Lilly Oncology Infused Products Co‑pay Program
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• First-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer
Patient support services
• Merck Co‑pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Lonsurf (trifluridine + tipiracil) Tablets
Drug company
• Taiho Oncology
Indication
• Treatment of metastatic colorectal cancer, after chemotherapy or other therapies
Patient support services
• Taiho Oncology Patient Support Co‑pay Card
  844-824-4648
  
  Taiho Oncology Patient Support Program
  844-824-4648

Drug name (generic name)
• Mvasi (bevacizumab-awwb)
Drug company
• Amgen
Indication
• Treatment of metastatic colorectal cancer, in combination with chemotherapy, or after disease progression with a bevacizumab-containing regimen
Patient support services
• Amgen FIRST STEP Co‑pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment, alone or in combination with Yervoy, of patients age 12 or older with MSI-H or dMMR metastatic colorectal cancer that progressed after chemotherapy
Patient support services
• BMS Oncology Co‑pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Stivarga (regorafenib) Tablets
Drug company
• Bayer
Indication
• Treatment of metastatic colorectal cancer, after chemotherapy or other therapies
Patient support services
• STIVARGA $0 Co‑pay Program
  866-581-4992
  
  Bayer US Patient Assistance Foundation
  866-228-7723

Drug name (generic name)
• Vectibix (panitumumab)
Drug company
• Amgen
Indication
• First-line therapy of metastatic colorectal cancer, in combination with chemotherapy
  
  Metastatic colorectal cancer, after chemotherapy
Patient support services
• Amgen FIRST STEP Co‑pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Xeloda (capecitabine) Tablets
Drug company
• Genentech
Indication
• Adjuvant therapy for colon cancer, specifically Dukes’ C colon cancer
  
  First-line therapy for metastatic colorectal cancer
Patient support services
• Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Yervoy (ipilimumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment, in combination with Opdivo, of patients age 12 or older with MSI-H or dMMR metastatic colorectal cancer that progressed after chemotherapy
Patient support services
• BMS Oncology Co‑pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Zirabev (bevacizumabbvzr)
Drug company
• Pfizer
Indication
• First- or second-line treatment, in combination with fluorouracil-based chemotherapy, of metastatic colorectal cancer
  
  Second-line treatment, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, of metastatic colorectal cancer in patients whose disease progressed during a first-line regimen containing a bevacizumab drug
Patient support services
• Pfizer Oncology Together Co‑pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675

dMMR indicates mismatch repair-deficient; MSI-H, microsatellite instability-high.